1 – 10 of 84
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- 2016
- Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer
- Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)
- Melanoma burden by melanoma stage : assessment through a disease transition model
- Cost-effectiveness analysis in melanoma detection: a transition model applied to dermoscopy
- 2015
- Responding to the cancer crisis: expanding global access to radiotherapy: a Lancet Oncology Commission
- Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
- Immunohistochemical analysis of CD70 expression in 95 cases of squamous cell carcinoma of the head and neck: correlation with clinicopathological variables and identification of a novel therapeutic target
- The Prostate Cancer Registry: first results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
- 2014
- Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation